63 related articles for article (PubMed ID: 22053714)
21. NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance.
Ballerini P; Busson M; Fasola S; van den Akker J; Lapillonne H; Romana SP; Marynen P; Bernard OA; Landman-Parker J; Berger R
Leukemia; 2005 Mar; 19(3):468-70. PubMed ID: 15674415
[No Abstract] [Full Text] [Related]
22. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles.
Fulci V; Colombo T; Chiaretti S; Messina M; Citarella F; Tavolaro S; Guarini A; Foà R; Macino G
Genes Chromosomes Cancer; 2009 Dec; 48(12):1069-82. PubMed ID: 19760605
[TBL] [Abstract][Full Text] [Related]
23. Genomic organization of the putative human homeobox proto-oncogene HOX-11 (TCL-3) and its endogenous expression in T cells.
Lu M; Zhang N; Ho AD
Oncogene; 1992 Jul; 7(7):1325-30. PubMed ID: 1352396
[TBL] [Abstract][Full Text] [Related]
24. High-resolution genomic profiling of pediatric lymphoblastic lymphomas reveals subtle differences with pediatric acute lymphoblastic leukemias in the B-lineage.
Schraders M; van Reijmersdal SV; Kamping EJ; van Krieken JH; van Kessel AG; Groenen PJ; Hoogerbrugge PM; Kuiper RP
Cancer Genet Cytogenet; 2009 May; 191(1):27-33. PubMed ID: 19389505
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D3 deregulation by juxtaposition with IGH locus in a t(6;14)(p21;q32)-positive T-cell acute lymphoblastic leukemia.
Nguyen-Khac F; Barin C; Chapiro E; Macintyre EA; Romana S; Bernard OA
Leuk Res; 2010 Jan; 34(1):e13-4. PubMed ID: 19665788
[No Abstract] [Full Text] [Related]
26. Genetic inactivation of Ikaros is a rare event in human T-ALL.
Marçais A; Jeannet R; Hernandez L; Soulier J; Sigaux F; Chan S; Kastner P
Leuk Res; 2010 Apr; 34(4):426-9. PubMed ID: 19796813
[TBL] [Abstract][Full Text] [Related]
27. MEIS proteins as partners of the TLX1/HOX11 oncoprotein.
Milech N; Gottardo NG; Ford J; D'Souza D; Greene WK; Kees UR; Watt PM
Leuk Res; 2010 Mar; 34(3):358-63. PubMed ID: 19559479
[TBL] [Abstract][Full Text] [Related]
28. Malignancy-Associated Hypercalcemia Related with Receptor Activator of NF-κB Ligand (RANKL) Expression in T-Cell Acute Lymphoblastic Leukemia.
Tahara K; Koiso H; Osaki YH; Sekigami T; Yokohama A; Saitoh T; Tsukamoto N; Murakami H; Abe M; Handa H
Acta Haematol; 2019; 141(3):135-137. PubMed ID: 30783036
[No Abstract] [Full Text] [Related]
29. CANCER. The oncogene makes its escape.
Wala J; Beroukhim R
Science; 2016 Mar; 351(6280):1398-9. PubMed ID: 27013717
[No Abstract] [Full Text] [Related]
30. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia.
Van Vlierberghe P; Pieters R; Beverloo HB; Meijerink JP
Br J Haematol; 2008 Oct; 143(2):153-68. PubMed ID: 18691165
[TBL] [Abstract][Full Text] [Related]
31. [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review].
He GS; Zhang XH; Yao L; Zhang R; Chen ZX; Wu DP; Sun AN; Jin ZM; Qiu HY; Hu XH
Zhonghua Xue Ye Xue Za Zhi; 2009 Oct; 30(10):675-7. PubMed ID: 19954663
[TBL] [Abstract][Full Text] [Related]
32. An X-linked tumor suppressor in T-ALL.
Ariës IM; Gutierrez A
Blood; 2015 Jan; 125(1):3-4. PubMed ID: 25554741
[No Abstract] [Full Text] [Related]
33. Controlling pre-leukemic thymocyte self-renewal.
Goossens S; Van Vlierberghe P
PLoS Genet; 2014 Dec; 10(12):e1004881. PubMed ID: 25522333
[No Abstract] [Full Text] [Related]
34. ETP-ALL with aberrant B marker expression: Case series and a brief review of literature.
Garg S; Gupta SK; Bakhshi S; Mallick S; Kumar L
Int J Lab Hematol; 2019 Apr; 41(2):e32-e37. PubMed ID: 30407727
[No Abstract] [Full Text] [Related]
35. T-ALL and thymocytes: a message of noncoding RNAs.
Wallaert A; Durinck K; Taghon T; Van Vlierberghe P; Speleman F
J Hematol Oncol; 2017 Mar; 10(1):66. PubMed ID: 28270163
[TBL] [Abstract][Full Text] [Related]
36. BCL7A protein expression in normal and malignant lymphoid tissues.
Ramos-Medina R; Montes-Moreno S; Maestre L; Cañamero M; Rodríguez-Pinilla M; Martínez-Torrecuadrada J; Piris MÁ; Majid A; Dyer MJ; Pulford K; Roncador G
Br J Haematol; 2013 Jan; 160(1):106-9. PubMed ID: 23043359
[No Abstract] [Full Text] [Related]
37. Elucidation of the methods used for quantitative analysis of radiolabeled sphingolipids with beta imager 2000 radiochromatoscanner in MOLT-4 leukemic cells.
Venerando B
Int J Cancer; 2017 Jun; 140(12):2831-2832. PubMed ID: 28340514
[No Abstract] [Full Text] [Related]
38. Genetic and epigenetic determinants mediate proneness of oncogene breakpoint sites for involvement in TCR translocations.
Larmonie NS; van der Spek A; Bogers AJ; van Dongen JJ; Langerak AW
Genes Immun; 2014 Mar; 15(2):72-81. PubMed ID: 24304972
[TBL] [Abstract][Full Text] [Related]
39. Correct interpretation of T-ALL oncogene expression relies on normal human thymocyte subsets as reference material.
Larmonie NS; Dik WA; van der Velden VH; Hoogeveen PG; Beverloo HB; Meijerink JP; van Dongen JJ; Langerak AW
Br J Haematol; 2012 Apr; 157(1):142-6. PubMed ID: 22053714
[No Abstract] [Full Text] [Related]
40. [Deciphering functional activity of TLX homeodomain oncogenes in T-ALL: a clue for a differentiating therapy?].
Asnafi V; Ferrier P
Med Sci (Paris); 2012; 28(8-9):708-10. PubMed ID: 22920872
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
